NASDAQ: OPTNOptinose Inc Stock
$0.91-0.02 (-2.15%)
Updated Apr 25, 2024
OPTN Price
$0.91
Fair Value Price
N/A
Market Cap
$101.95M
52 Week Low
$0.86
52 Week High
$2.10
P/E
-2.83x
P/B
-1.18x
P/S
2.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$70.99M
Earnings
-$35.48M
Gross Margin
87.8%
Operating Margin
-22.48%
Profit Margin
-50%
Debt to Equity
-2.24
Operating Cash Flow
-$21M
Beta
0.86
Next Earnings
Jun 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
OPTN Overview
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OPTN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OPTN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OPTN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
OPTN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more OPTN due diligence checks available for Premium users.
Be the first to know about important OPTN news, forecast changes, insider trades & much more!
OPTN News
Valuation
OPTN fair value
Fair Value of OPTN stock based on Discounted Cash Flow (DCF)
Price
$0.91
Fair Value
-$0.04
Undervalued by
2,143.63%
OPTN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OPTN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.83x
Industry
33.56x
Market
40.97x
OPTN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.18x
Industry
2.07x
OPTN's financial health
Profit margin
Revenue
$19.9M
Net Income
-$10.0M
Profit Margin
-50.2%
OPTN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
OPTN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$107.7M
Liabilities
$194.3M
Debt to equity
-2.24
OPTN's short-term liabilities ($176.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OPTN's short-term assets ($105.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OPTN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OPTN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$6.9M
Investing
-$73.0k
Financing
$4.0k
OPTN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OPTN vs Pharmaceutical Stocks
Optinose Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.